NCT06011083

Topical Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis

Completed NA Last updated 25 August 2023

What this trial tests

NA trial testing Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm in Psoriasis Vulgaris in 40 participants. Completed in 1 August 2023.

Timeline

1 August 2022

Primary endpoint
28 February 2023

1 August 2023

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	1 August 2022
Primary completion	28 February 2023
Estimated completion	1 August 2023
Sites	1 location across Egypt

Drugs / interventions tested

• Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm — full drug profile →
• Fractional carbon dioxide (CO2) laser

Conditions studied

• Psoriasis Vulgaris — all drugs for Psoriasis Vulgaris →
• Fractional CO2 Laser — all drugs for Fractional CO2 Laser →

Sponsor

Assiut University

Who can join

Adults 18 to 60, any sex, with Psoriasis Vulgaris or Fractional CO2 Laser. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

comparing the clinical efficacy of topical ointment containing calcipotriol and betamethasone dipropionate used alone with the simultaneous use of fractional carbon dioxide laser and the same topical ointment containing these two ingredients as treatment modalities for plaque psoriasis. Additionally, looking into how both therapy modalities affect individuals with psoriasis in terms of how their quality of life is improved.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.